Form 4: Heron Therapeutics EVP Ira Duarte Reports Stock Transactions
SEC Form 4 Filing
Ira Duarte, EVP and CFO of Heron Therapeutics, reports the vesting of restricted stock units into common stock.
Summary
- On October 19, 2024, Ira Duarte, the EVP and Chief Financial Officer of Heron Therapeutics, Inc., reported a transaction involving the vesting of restricted stock units.
- Duarte converted 3,874 restricted stock units into common stock.
- Following the transaction, Duarte directly owns 108,001 shares of common stock and 50,366 restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral event, reflecting routine executive compensation and stock transactions. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is standard practice for publicly traded companies to ensure transparency and compliance with SEC regulations.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it is a routine executive compensation matter.
Key Dates
| Date | Description |
|---|---|
| 01/19/2024 | Date of grant for restricted stock units, which vest in 16 equal quarterly installments beginning one quarter after this date. |
| 10/19/2024 | Date of transaction: conversion of restricted stock units into common stock. |
| 10/21/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.